Selzentry, Celsentri (maraviroc) is a small molecule pharmaceutical. Maraviroc was first approved as Selzentry on 2007-08-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against C-C chemokine receptor type 5. In addition, it is known to target Rubredoxin. Selzentry's patents are valid until 2022-11-25 (FDA).
|Drug Class||Antivirals; CCR5 antagonists|